Docoh
Loading...

AERI Aerie Pharmaceuticals

News

Pro users get this 30m faster
The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology
12 Oct 21
Biotech, Earnings, News, Penny Stocks, Offerings, Small Cap, FDA
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 11)
The Week Ahead In Biotech (Oct. 10-16): Avadel FDA Decision, Conference Presentations And IPOs Take Center Stage
10 Oct 21
Biotech, Earnings, News, FDA, IPOs
Biotech stocks retreated in the week ending Oct. 8, extending losses for the third straight week. Some of the selling in the space was due to money moving out of defensive stocks and into risky bets amid the broader market strength.
Aerie Pharmaceuticals Announces Presentation At The Ophthalmology Innovation Summit Retina Innovation Showcase
7 Oct 21
News, Events
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company, today announced that Casey Kopczynski, Ph.D., Chief Scientific Officer presented an overview on Aerie’s retina product candidates, at
The Daily Biotech Pulse: Aprea Jumps On ESMO Presentation, Verrica Sinks On Regulatory Setback, Aerie CEO Quits, J&J Touts Positive COVID-19 Booster Shot Data
21 Sep 21
Biotech, M&A, News, Penny Stocks, Offerings, Small Cap, FDA, Legal, General
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 20)
56 Biggest Movers From Yesterday
17 Sep 21
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Mid-Afternoon Market Update: Dow Falls 70 Points; Aerie Pharmaceuticals Shares Plunge
16 Sep 21
Earnings, News, Penny Stocks, Eurozone, Commodities, Small Cap, Global, Intraday Update, Markets
Toward the end of trading Thursday, the Dow traded down 0.20% to 34,745 while the NASDAQ fell 0.03% to 15,157.61. The S&P also fell, dropping 0.21% to 4,471.34.
12 Health Care Stocks Moving In Thursday's Intraday Session
16 Sep 21
Intraday Update, Markets, Movers
Mid-Day Market Update: Gold Drops Over 2%; Leap Therapeutics Shares Jump
16 Sep 21
Earnings, News, Penny Stocks, Eurozone, Commodities, Small Cap, Global, Intraday Update, Markets
Midway through trading Thursday, the Dow traded down 0.74% to 34,557.75 while the NASDAQ fell 0.67% to 15,060.25. The S&P also fell, dropping 0.79% to 4,445.34.
38 Stocks Moving In Thursday's Mid-Day Session
16 Sep 21
News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas
Gainers IronNet Cybersecurity, Inc. (NASDAQ: IRNT) shares jumped 30.4% to $41.90 amid increased retail investor interest in the stock on social media.
Mid-Morning Market Update: Markets Down; US Retail Sales Unexpectedly Increase in August
16 Sep 21
Earnings, News, Eurozone, Commodities, Small Cap, Global, Intraday Update, Markets
Following the market opening Thursday, the Dow traded down 0.45% to 34,657.69 while the NASDAQ fell 0.66% to 15,061.97. The S&P also fell, dropping 0.62% to 4,453.04.
12 Health Care Stocks Moving In Thursday's Pre-Market Session
16 Sep 21
Pre-Market Outlook, Markets, Movers
The Daily Biotech Pulse: Leap, Phio, Silverback Among Early Movers On Oncology Conference Presentations, Aerie Slumps On Mixed Data, Axsome Commences Phase 3 Sleep Disorder Study
16 Sep 21
Biotech, News, Penny Stocks, Offerings, Small Cap, FDA, General
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 15)
20 Stocks Moving in Thursday's Pre-Market Session
16 Sep 21
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Gainers IronNet Cybersecurity, Inc. (NASDAQ: IRNT) rose 59.7% to $51.30 in pre-market trading. IronNet Cybersecurity emerged as the most-discussed stock on Reddit’s r/WallStreetBets forum as of Wednesday night.
Aerie Pharma Reports Mixed Bag On Phase 2 Dry Eye Trial
16 Sep 21
Biotech, News, Health Care, Small Cap, FDA, General
12 Health Care Stocks Moving In Wednesday's After-Market Session
15 Sep 21
Movers
Gainers
Aerie Pharmaceuticals Announces Novel Dry Eye Product Candidate AR-15512 Ophthalmic Solution Achieved Statistical Significance Over Multiple Symptoms And Signs In Successful Phase 2b Clinical Study For The Treatment Of Dry Eye Disease
15 Sep 21
Biotech, General
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle
USPTO Site Shows Aerie Pharmaceuticals Granted Patent 'Compounds, compositions and methods for treatment of myopia'
14 Sep 21
Biotech, General
https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=5484&f=G&l=50&d=PTXT&p=110&S1=20210914&OS=20210914&RS=20210914
Looking into Aerie Pharmaceuticals's Return on Capital Employed
20 Aug 21
Earnings
After pulling data from Benzinga Pro it seems like during Q2, Aerie Pharmaceuticals (NASDAQ:AERI) posted sales of $27.18 million. Earnings were up 7.94%, but Aerie Pharmaceuticals still reported an overall loss of $31.50 million.
12 Health Care Stocks Moving In Tuesday's After-Market Session
10 Aug 21
Movers
Gainers
Needham Maintains Buy on Aerie Pharmaceuticals, Lowers Price Target to $24
5 Aug 21
News, Price Target, Analyst Ratings
Needham analyst Serge Belanger maintains Aerie Pharmaceuticals (NASDAQ:AERI) with a Buy and lowers the price target from $26 to $24.

Press releases

Pro users get this 30m faster
Thinking about buying stock in Ocugen, aTyr Pharma, Nextplay Technologies, Aerie Pharmaceuticals, or Nutriband?
12 Oct 21
Opinion, Press Releases
NEW YORK, Oct. 12, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for OCGN, LIFE, NXTP, AERI, and NTRB.
Aerie Pharmaceuticals Announces Positive Phase 3 Topline Results for Netarsudil Ophthalmic Solution 0.02% Clinical Trial in Japan
12 Oct 21
Press Releases
Netarsudil Ophthalmic Solution 0.02% Once Daily Demonstrated Superiority to Ripasudil 0.4% Twice Daily Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company, today reported positive topline
Aerie Pharmaceuticals Announces Presentation at the Ophthalmology Innovation Summit Retina Innovation Showcase
7 Oct 21
Press Releases
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company, today announced that Casey Kopczynski, Ph.D., Chief Scientific Officer presented an overview on Aerie's retina product candidates, at the
Aerie Pharmaceuticals Announces Presentation at the 39th Annual Scientific Meeting of the American Society of Retina Specialists
6 Oct 21
Press Releases
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company, today announced that topline results from the AR-1105 (dexamethasone intravitreal implant) Phase 2 clinical trial in patients with macular
Aerie Pharmaceuticals to Participate in the Cantor Global Healthcare Conference
27 Sep 21
Press Releases
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle
Aerie Pharmaceuticals, Inc. Announces the Appointment of Interim Executive Chair and Departure of Chairman and CEO
21 Sep 21
Press Releases
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company, today announced that it is executing its succession plan for its long-serving Chairman and CEO and that effective September 17, 2021,
Aerie Pharmaceuticals Announces Appointment of Erik Pacyniak, Ph.D., D.A.B.T., as Director, Toxicology and Drug Disposition
20 Sep 21
Press Releases
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle
Aerie Pharmaceuticals Announces Novel Dry Eye Product Candidate AR-15512 (TRPM8 Agonist) Ophthalmic Solution Achieved Statistical Significance Over Multiple Symptoms and Signs in Successful Phase 2b Clinical Study for the Treatment of Dry Eye Disease
15 Sep 21
Press Releases
AR-15512 (0.003%) BID Advancing to Phase 3; No Treatment-Related Serious or Systemic Adverse Events Reported Conference Call and Webcast Today, September 15th, at 5:00 p.m. ET Aerie Pharmaceuticals, Inc.
Aerie Pharmaceuticals Announces Appointment of Carolyn McAuliffe, Senior Director, Communications
13 Sep 21
Press Releases
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle
Aerie Pharmaceuticals to Participate in Upcoming Investor Conferences
7 Sep 21
Press Releases
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle
Aerie Pharmaceuticals Announces Appointment of Michael Bradley, Senior Director, Manufacturing
7 Sep 21
Press Releases
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle
Aerie Pharmaceuticals to Participate in the H.C. Wainwright Ophthalmology Conference
12 Aug 21
Press Releases
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle
Aerie Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Business Update
4 Aug 21
Press Releases
Second Quarter 2021 Net Revenues of $27.2 Million Increased 50.8% over Second Quarter 2020 Second Quarter 2021 Net Revenue Per Bottle of $89, up 14.7% over Second Quarter 2020 Phase 2b Topline Results for AR-15512
Aerie Pharmaceuticals to Announce Second Quarter 2021 Financial Results and Host Conference Call on Wednesday, August 4, 2021
28 Jul 21
Press Releases
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle
Aerie Pharmaceuticals Announces Presentation at the Ophthalmology Innovation Summit European Innovation Showcase
20 Jul 21
Press Releases
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle